Salbutamol vs placebo/no treatment
Duration of oxygen therapy (hours) · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
- no estimate extracted4 studies · 338 participantsVery low
Findings
What do systematic reviews say?
11 questions · 11 findings · 2 reviews · Neonatal
No studies found 2 · 18.2%GRADE not reported 0 · 0%Very low 6 · 54.5%Low 3 · 27.3%Moderate 0 · 0%High 0 · 0%
Salbutamol vs placebo/no treatment
Need for continuous positive airway pressure (yes/no) · patients with the management of transient tachypnea of the newborn
It is very uncertain whether salbutamol changes need for continuous positive airway pressure (yes/no) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
- RR 0.73 [0.38, 1.39]1 study · 46 participantsVery low
Salbutamol vs placebo/no treatment
Need for mechanical ventilation · patients with the management of transient tachypnea of the newborn
It is very uncertain whether salbutamol changes need for mechanical ventilation (yes/no) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
- RR 0.6 [0.13, 2.86]3 studies · 254 participantsVery low
Salbutamol vs placebo/no treatment
Duration of respiratory support (intermittent positive pressure ventilation or continuous positive airway pressure; hours). · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
- no estimate extracted2 studies · 228 participantsVery low
Salbutamol vs placebo/no treatment
Length of hospital stay · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
- no estimate extracted4 studies · 338 participantsLow
Salbutamol vs placebo/no treatment
Duration of mechanical ventilation · patients with the management of transient tachypnea of the newborn
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Salbutamol vs placebo/no treatment
Pneumothorax · patients with the management of transient tachypnea of the newborn
It is very uncertain whether salbutamol changes pneumothorax (yes/no) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
- no estimate extracted1 study · 80 participantsVery low
Salbutamol vs placebo
Mortality within the trial period · preterm infants (< 37 weeks GA) at risk of chronic lung disease
Summary of findings table ‐ Salbutamol showed no clear difference in mortality within the trial period compared with placebo (low certainty).
1 finding from 1 review
- Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants 2024 · Cochrane Headline outcomes onlyRR 1.08 [0.5, 2.31]1 study · 173 participantsLow
Salbutamol vs placebo
Chronic lung disease · preterm infants (< 37 weeks GA) at risk of chronic lung disease
Summary of findings table ‐ Salbutamol showed no clear difference in chronic lung disease at 28 days compared with placebo (low certainty).
1 finding from 1 review
- Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants 2024 · Cochrane Headline outcomes onlyRR 1.03 [0.78, 1.37]1 study · 173 participantsLow
Salbutamol vs placebo
Hypokalaemia · preterm infants (< 37 weeks GA) at risk of chronic lung disease
The review found no eligible studies for this question.
1 finding from 1 review
- Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants 2024 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Salbutamol vs placebo
Pneumothorax · preterm infants (< 37 weeks GA) at risk of chronic lung disease
1 finding from 1 review
- Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants 2024 · Cochrane Headline outcomes onlyno estimate extracted1 study · 173 participantsVery low